Jim Tananbaum is the founder and CEO of Foresite Capital. He founded the company in 2011 as a private equity firm dedicated to healthcare specializing in pinpointing and growing future market leaders by offering capital, information, and networks. He is a Yale, Harvard, and M.I.T. graduate, having obtained a math and computer science/ electrical engineering degree from Yale, an M.D. and M.B.A. from Harvard, and an M.S. from M.I.T.
Before founding Foresite Capital, Jim had already co-founded two healthcare investment practices and two top biopharmaceutical companies. He founded GelTex Pharmaceuticals which introduced two drugs into the market for less than $80 million. The company was then acquired for $1.6 billion in 1998. Jim also co-founded Theravance, Inc where he served as the CEO.
His vision for starting Foresite was to marry all the elements he had picked up in his career and create a great investment platform. Theravance, Inc. has a joint venture with Innoviva and shares GSK’s respiratory franchise, completing a spinoff, Theravance Biopharma, Inc. These two companies have approximately $3.2 billion in combined market capitalization. Visit pelotontherapeutics.com
Earlier in his career, Jim was a partner at Sierra Ventures where he was instrumental in establishing its investment practice in health care services. He was also one of the founding partners of Prospect Venture Partners II and III. His numerous investments include Amira Pharmaceuticals, Amerigroup, Jazz Pharmaceuticals, and Healtheon.
According to INC42, Foresite Capital invested in Aeri Pharmaceuticals, which has brought a once daily glaucoma treatment to the market. The company has also been at the forefront in quite a few investments in synthetic biology and sequencing. Despite receiving its first institutional capital in 2013, Foresite has invested in many healthcare leaders in Pharmaceuticals that are emerging, synthetic biology, gene sequencing, healthcare delivery, and data science.
Jim admits that his love for learning has considerably contributed to his success. He may be focusing on the business-arm of healthcare, but he views himself as an academic at heart. It is his passion for learning that has driven him to find some of the best scientific solutions. He has coupled his passion with persistence and commitment to push him to continue building his firm and expanding their innovative portfolio.